
1. General Information
Spnib 70 mg Tablet is an anti-cancer prescription medicine containing Dasatinib 70 mg. Dasatinib belongs to the class of medicines known as tyrosine kinase inhibitors (TKIs). It is primarily used for certain Philadelphia chromosome-positive (Ph+) blood cancers, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Spnib 70 mg is an oral medicine and should be taken strictly according to the treatment plan prescribed by an oncologist or other qualified healthcare professional.
2. Product Information
- Brand: Spnib 70 mg Tablet
- Active ingredient: Dasatinib
- Strength: 70 mg
- Dosage form: Tablet
- Therapeutic category: Antineoplastic / targeted cancer therapy
- Drug class: Tyrosine kinase inhibitor
- Primary targets: BCR-ABL and Src-family kinases
- Typical pack: 60 tablets, depending on the market and manufacturer packaging
- Route: Oral
- Prescription status: Prescription medicine
- Manufacturer/Marketer: Zydus Lifesciences Ltd.
Phoenix Exim is a pharmaceutical exporter based in Nagpur, India, serving international B2B pharmaceutical enquiries for markets including the USA, UK, Australia, Singapore, Canada, South Korea and UAE, subject to applicable import, registration and prescription requirements.
3. Uses of Spnib 70 mg
Spnib 70 mg is used under specialist medical supervision for certain blood cancers, particularly:
- Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
- Certain CML cases where previous treatment has not worked adequately or was not tolerated
- Specific leukemia treatment situations determined by an oncologist
The exact indication and treatment regimen depend on the patient's disease characteristics and previous therapy.
4. Benefits of This Medicine
The potential therapeutic benefits of dasatinib include:
- Helps inhibit abnormal cancer-related signaling.
- Targets the BCR-ABL tyrosine kinase, an important driver in Philadelphia chromosome-positive leukemia.
- Also inhibits certain Src-family kinases involved in cancer-cell signaling.
- Helps reduce the abnormal multiplication of leukemia cells.
- Provides a targeted treatment option for appropriate patients with Ph+ leukemia.
The expected benefit varies between patients and should be assessed through regular medical monitoring.
5. Side Effects of Spnib 70 mg
Like other anti-cancer medicines, Spnib 70 mg can cause adverse effects. Some may be mild, while others require prompt medical attention.
Possible side effects include:
- Diarrhea
- Nausea
- Vomiting
- Headache
- Fatigue or weakness
- Muscle or musculoskeletal pain
- Skin rash
- Abdominal discomfort or pain
- Reduced blood-cell counts
- Fluid retention
- Shortness of breath
- Gastrointestinal bleeding in some patients
Patients should contact their healthcare professional if symptoms are severe, persistent or unusual.
6. Common Side Effects
Commonly reported effects associated with dasatinib may include:
- Fatigue
- Headache
- Nausea
- Diarrhea
- Vomiting
- Skin rash
- Muscle or joint pain
- Abdominal pain
- Reduced appetite
- Low blood-cell counts
- Fluid retention
The severity and frequency can vary according to the patient's condition, dose and other medicines being taken.
7. How to Use Spnib 70 mg
Spnib 70 mg should be taken exactly as prescribed by the treating physician.
General administration information:
- Take the tablet orally with water.
- It may generally be taken with or without food.
- Swallow the tablet whole.
- Do not crush, chew or break the tablet unless specifically instructed by a healthcare professional.
- Try to take it at approximately the same time each day.
- Do not change the dose or stop treatment without medical advice.
- If a dose is missed, follow the instructions provided by the treating physician or product information rather than taking an extra dose.
Important: The appropriate dose and treatment duration depend on the leukemia type, treatment history, age and clinical response. A 70 mg strength should not automatically be interpreted as the correct dose for every patient.
8. How Spnib 70 mg Works
Spnib contains dasatinib, which blocks several abnormal tyrosine kinases.
One of its major targets is the BCR-ABL protein, which is produced as a result of the Philadelphia chromosome abnormality found in many Ph+ leukemia cells. By inhibiting BCR-ABL and other relevant kinases, dasatinib interferes with signals that promote cancer-cell growth and survival. This helps suppress abnormal leukemia-cell proliferation.
9. Safety Advice
Because Spnib 70 mg is a potent anti-cancer prescription medicine, several precautions are important:
- Use only under the supervision of a qualified oncologist.
- Inform your doctor about all medicines, supplements and herbal products being taken.
- Tell your doctor if you have liver, kidney, heart or gastrointestinal problems.
- Dasatinib can cause myelosuppression, so blood counts may need regular monitoring.
- Report unusual bleeding, persistent fever, severe weakness or signs of infection promptly.
- Seek medical attention for significant breathing difficulties or swelling.
- Dasatinib may cause fetal harm; patients who can become pregnant should discuss effective contraception with their healthcare professional.
- Breastfeeding should generally be avoided during treatment as advised by the treating physician.
- Some medicines can interact with dasatinib, including certain CYP3A inhibitors/inducers and acid-reducing medicines.
- Grapefruit/grapefruit juice may interact with dasatinib and should be discussed with the treating physician.
- Do not self-medicate or use the medicine for conditions for which it has not been prescribed.
10. Frequently Asked Questions (FAQs)
Q1. What is Spnib 70 mg Tablet?
Spnib 70 mg is a prescription anti-cancer tablet containing dasatinib 70 mg, a tyrosine kinase inhibitor used for certain types of leukemia.
Q2. What is Spnib 70 mg used for?
It is used for specific Philadelphia chromosome-positive CML and Ph+ ALL under specialist medical supervision.
Q3. Is Spnib 70 mg a chemotherapy medicine?
It is an anti-cancer medicine, but more specifically it is classified as a targeted tyrosine kinase inhibitor rather than traditional cytotoxic chemotherapy.
Q4. What is the active ingredient in Spnib 70 mg?
The active ingredient is dasatinib 70 mg.
Q5. Can Spnib 70 mg be taken without a prescription?
No. It is a prescription anti-cancer medicine and should only be used following appropriate medical evaluation and prescription.
Q6. Can Spnib 70 mg be stopped suddenly?
Do not stop dasatinib without consulting the treating oncologist. Treatment duration and discontinuation should be medically supervised.
Q7. Can Spnib 70 mg be taken with food?
Available product information states that it can generally be taken with or without food. Follow the specific instructions provided by your healthcare professional.
Q8. What should I do if I miss a dose?
Follow your physician's or product leaflet's missed-dose instructions. Do not take an extra dose to compensate unless specifically instructed.
Q9. Does Spnib 70 mg interact with other medicines?
Yes. Dasatinib has clinically important drug interactions, including with some CYP3A inhibitors/inducers and certain acid-reducing medicines. Always provide your doctor with a complete list of medicines you take.
Q10. Who should supply or purchase Spnib 70 mg internationally?
International pharmaceutical transactions should be conducted through appropriately licensed/authorized channels and comply with the importing country's medicine, prescription, customs and regulatory requirements.
11. Substitutes for Spnib 70 mg
Potential alternatives may contain the same active ingredient dasatinib 70 mg, but a substitute should only be selected after confirmation by the treating physician or pharmacist.
Examples of dasatinib products/brands may vary by country and market. The correct substitute should match:
- Active ingredient
- Strength
- Dosage form
- Approved indication
- Patient-specific prescription
- Applicable regulatory requirements
A lower-priced or different brand should not automatically be considered equivalent for an individual patient.
12. SEO & B2B Keywords
Product Keywords
- Spnib 70 mg Tablet
- Spnib 70 mg Dasatinib Tablet
- Spnib 70 mg tablets exporter
- Spnib 70 mg supplier India
- Spnib 70 mg pharmaceutical exporter
- Dasatinib 70 mg tablet exporter
- Dasatinib 70 mg supplier India
- Dasatinib 70 mg medicine exporter
- Spnib 70 mg wholesale supplier
- Spnib 70 mg pharmaceutical supplier
Cancer & Therapeutic Keywords
- Dasatinib 70 mg for CML
- Spnib 70 mg for leukemia
- Dasatinib for chronic myeloid leukemia
- Dasatinib for Philadelphia chromosome positive leukemia
- Ph+ CML medicine supplier
- Ph+ ALL medicine exporter
- tyrosine kinase inhibitor supplier India
- leukemia medicine exporter India
- anti cancer medicine exporter India
- oncology medicine supplier India
B2B / Export Keywords
- Spnib 70 mg exporter from Nagpur India
- Spnib 70 mg supplier from India
- Dasatinib exporter from Nagpur
- pharmaceutical exporter Nagpur India
- oncology medicine exporter India
- anti cancer medicine supplier India
- Spnib 70 mg export supplier
- Dasatinib 70 mg B2B supplier
- pharmaceutical wholesale supplier India
- international pharmaceutical exporter India
- Spnib 70 mg supplier USA
- Spnib 70 mg supplier UK
- Spnib 70 mg supplier Australia
- Spnib 70 mg supplier Canada
- Spnib 70 mg supplier Singapore
- Spnib 70 mg supplier South Korea
- Spnib 70 mg supplier UAE
Phoenix Exim SEO Phrases
- Phoenix Exim Spnib 70 mg exporter Nagpur India
- Phoenix Exim Dasatinib 70 mg pharmaceutical supplier
- Phoenix Exim oncology medicine exporter India
- Phoenix Exim anti cancer medicine supplier Nagpur
- Phoenix Exim international pharmaceutical exporter
- Spnib 70 mg Dasatinib supplier Phoenix Exim
- trusted pharmaceutical exporter from Nagpur India
- Spnib 70 mg B2B pharmaceutical export supplier
Keywords







